Biofil Chemicals & Pharmaceuticals share price & results
- Jun 2026
- Jun 2026
Indore (Pithampur) manufacturer of pharmaceutical bulk drugs and excipients — ferrous sulphate, MCCP, cellulose powder, diclofenac sodium and other allied APIs.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 12.4 | +92.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 1.1 | +1.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 0.11 | −95.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 2.38 | −4.1 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 1.90 | +7.9 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 9.33 | +1.6 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −23.2% 1Y
1Y: ₹38.96 on 24 Oct 2025 → ₹29.92. High ₹46.34 (3 Feb 2026), low ₹25.79 (30 Mar 2026).
- Previous close
- ₹28.03
- Market cap
- ₹53 Cr
- 52-week range
- ₹25.79 – ₹46.34
- One year
- −23.01%
- Price to earnings (TTM to Jun 2026)
- 111.25×
- Return on equity (TTM to Jun 2026)
- 2.38%
Overview
- Symbol
- NSE:BIOFILCHEM
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Biofil Chemicals & Pharmaceuticals Limited does
Based on the company's own presentations, annual report and earnings calls.
Biofil Chemicals & Pharmaceuticals manufactures pharmaceutical bulk drugs, APIs and excipients at its Pithampur (Indore) unit, with commercial production running since September 1993. Its product range spans Dried Ferrous Sulphate (crystal, exsiccated and granular forms), Microcrystalline Cellulose Powder (MCCP) and Cellulose Powder, alongside bulk drugs such as Diclofenac Sodium, Aceclofenac, Mefenamic Acid and Fenbendazole. The unit produces, purchases, sells, exports, imports and trades these pharmaceutical and chemical products, with finished goods also supplied as raw material to related entity Cyano Pharma Private Limited.
Segments
- Bulk drugs / APIs
- Pharmaceutical excipients & specialty chemicals
- Manufacturing units
- 1 (Pithampur, Indore) — operations consolidating after disposal of the Sanwer Road, Indore unit
- Commercial production commenced
- September 1993
- Product portfolio
- 9 bulk-drug/API and excipient products across ferrous sulphate, cellulose derivatives and analgesic APIs
- Operations
- Production, export, import and trading of pharmaceutical & chemical products
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −95% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 14 | 8 | 6 | 14 | 1 | 8 | 12 |
| Expenses | 2 | 14 | 8 | 6 | 13 | 1 | 7 | 12 |
| Operating profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating margin | 5.0% | 2.2% | 1.3% | 0.2% | 0.9% | 10.5% | 5.7% | 1.1% |
| Other income | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Tax rate | 33.3% | 27.3% | 23.1% | 12.7% | 27.3% | 30.0% | 55.3% | 23.1% |
| Net profit | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| EPS (₹ per share) | 0.01 | 0.10 | 0.12 | 1.48 | 0.05 | 0.05 | 0.13 | 0.07 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 40 | 33 | 28 |
| Expenses | 39 | 33 | 28 |
| Operating profit | 1 | 1 | 1 |
| Other income | 0 | 0 | 3 |
| Interest | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 1 | 1 | 3 |
| Net profit | 1 | 1 | 3 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 1 | 1 | 2 | 3 | 5 | 5 |
| Borrowings | 0 | 1 | 0 | 0 | 0 | 3 |
| Other liabilities | 1 | 14 | 28 | 32 | 34 | 18 |
| Total liabilities | 19 | 31 | 47 | 51 | 55 | 43 |
| Fixed assets | 9 | 9 | 9 | 8 | 7 | 7 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 9 | 22 | 38 | 43 | 48 | 36 |
| Total assets | 19 | 31 | 47 | 51 | 55 | 43 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 1 | -0 | -0 | 2 | -2 | -1 |
| Cash from investing | -0 | -0 | -0 | -0 | -0 | 1 |
| Cash from financing | -1 | -0 | 0 | -0 | 0 | 3 |
| Net cash flow | 0 | -0 | -0 | 2 | -2 | 3 |
| Free cash flow | 1 | -0 | -0 | 2 | -2 | 1 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 176 | 117 | 249 | 301 | 419 | 355 |
| Inventory days | 49 | 24 | 16 | 25 | 40 | 56 |
| Days payable | 178 | 11 | 168 | 268 | 367 | 240 |
| Cash conversion cycle | 46 | 130 | 97 | 58 | 92 | 171 |
| Working capital days | 64 | 125 | 104 | 69 | 114 | 152 |
| Return on capital employed | 12.2% | 6.2% | 4.7% | 4.9% | 4.1% | 3.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
Chemical Division contributes 74.6% of reported segment revenue.
Quarter ended 30 Jun 2026 · Standalone
- Chemical Division 74.6%
₹9.22 crore
- Pharma Division 25.4%
₹3.13 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| Chemical Division | 9.22 | 74.6% |
| Pharma Division | 3.13 | 25.4% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹12.35 crore
- Intersegment adjustment
- ₹0.00 crore
- Net segment revenue
- ₹12.35 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
Ownership
Who owns it
Public hold 53.13% as of Jun 2026; institutions added 0.00 pts since Mar 2026.
- Promoters 46.79%
- Foreign institutions 0.00%
- Domestic institutions 0.08%
- Public 53.13%
Who is on the register
Named in the Jun 2026 filing
Every holder of Biofil Chemicals & Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 13.90% | unchanged | |
| 7.22% | unchanged | |
| 7.07% | −0.44 pp | |
| 5.39% | unchanged | |
| 4.06% | unchanged | |
| 4.05% | unchanged | |
| 3.03% | unchanged | |
| 2.60% | unchanged | |
| 2.35% | unchanged | |
| 1.89% | unchanged | |
| 1.22% | unchanged | |
| 1.15% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Biofil Chemicals & Pharmaceuticals Limited
Free account: one company. Everything above stays public.
Write why you follow Biofil Chemicals & Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Biofil Chemicals & Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.